TickerFacts.

Company research / UPC

Universe Pharmaceuticals Inc (UPC)

Build a valuation ↗↓ Download CSV

SEC name Universe Pharmaceuticals INC · CIK 0001809616 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Sep 30

Figures out of scale. In this company's filings, reported revenue for the year ended 2023-09-30 is more than 100 times total assets. That usually means a value was tagged in the wrong unit. Figures are shown as filed; growth rates are not computed, and the company is left out of screens and comparisons.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 6-K (current report) · 2026-10-06

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Stock splits: 1-for-6, first reflected in a filing dated 2023-08-31. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period ended2025-09-302024-09-302023-09-302022-09-302021-09-302020-09-302019-09-30
Revenue$17.86B$23.02B$32.31B$40.14M$47.98M$30.70M$33.23M
Cost of Revenue$11.56B$16.95B$21.99B$18.25M$22.66M$16.61M$19.82M
Gross Profit$6.30B$6.07B$10.32B$21.89M$25.33M$14.09M$13.41M
R&D Expense$671.76M$3.03B$4.86B$7.64M$5.47M$583.1K$618.4K
Operating Income-$2.92B-$8.02B-$3.97B-$7.02M$13.59M$10.25M$9.75M
Depreciation & Amortization$517.43M$485.73M$508.79M$533.9K$446.9K$410.1K$418.4K
EBITDA-$2.40B-$7.53B-$3.46B-$6.49M$14.04M$10.66M$10.17M
Net Income-$3.67B-$8.73B-$6.58B-$7.91M$11.32M$7.56M$7.55M
EPS (Diluted)-$8.06-$626.96-$1089.21-$1309.11$3.58$0.47n/a
Total Assets$69.30B$67.95B$41.72M$59.54M$70.14M$28.80Mn/a
Total Liabilities$13.17B$22.45B$13.75Mn/an/an/an/a
Shareholders' Equity$56.13B$45.50B$27.97B$35.33M$58.93M$20.80M$12.38M
Cash & Equivalentsn/an/an/an/a$8.08M$10.06M$3.18M
Operating Cash Flow-$5.05B-$9.51B$1.12B-$1.30M-$2.06M$6.12M$13.20M
Capital Expenditures$266.77M$208.32M$44.17M$93.7K$444.5K$51.8K$86.3K
Free Cash Flow-$5.32B-$9.72B$1.07B-$1.40M-$2.50M$6.06M$13.12M
Dividends Paidn/an/an/an/an/an/a$16.00M
Shares Outstandingn/an/a3.62Mn/a21.75M16.00Mn/a
Weighted Average Diluted Sharesn/an/a3.62M6.0K3.16M16.00Mn/a
EPS (Basic)-$8.06-$626.96-$1089.21-$1309.11$3.58$0.47n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView